Response to letter commenting on published paper: Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis

Affiliations

¹ MRC Clinical Trials Unit at UCL, London, UK. Electronic address: larysa.rydzewska@ucl.ac.uk.
² MRC Clinical Trials Unit at UCL, London, UK.

Free article

Comment

Larysa H M Rydzewska et al. Eur J Cancer. 2018 May.

Free article

. 2018 May:94:218-219.

doi: 10.1016/j.ejca.2018.02.002. Epub 2018 Mar 13.

¹ MRC Clinical Trials Unit at UCL, London, UK. Electronic address: larysa.rydzewska@ucl.ac.uk.
² MRC Clinical Trials Unit at UCL, London, UK.

No abstract available

Comment on

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, Mason MD, Miladinovic B, James ND, Parmar MKB, Spears MR, Sweeney CJ, Sydes MR, Tran N, Tierney JF; STOPCaP Abiraterone Collaborators. Rydzewska LHM, et al. Eur J Cancer. 2017 Oct;84:88-101. doi: 10.1016/j.ejca.2017.07.003. Epub 2017 Aug 8. Eur J Cancer. 2017. PMID: 28800492 Free PMC article.
RE: Rydzewska et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. Eur J Cancer. 2017 Oct; 84:88-101.
Wallis CJD, Klaassen Z. Wallis CJD, et al. Eur J Cancer. 2018 May;94:216-217. doi: 10.1016/j.ejca.2018.01.115. Epub 2018 Mar 21. Eur J Cancer. 2018. PMID: 29573942 No abstract available.